SEC Form 4 · accession 0001817160-26-000017
Nurix Therapeutics, Inc. · NRIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gwenn Hansen
Officer — Chief Scientific Officer
Period of report
Aug 5, 2026
Accepted (ET)
Aug 5, 2026 · 6:59 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001549595
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 5, 2026 | M | 4,356 | $1.86 | A | 121,583 | D | |
| Common Stock | Aug 5, 2026 | S | 4,356 | $25.00 | D | 117,227 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $1.86 | Aug 5, 2026 | M | 4,356 | D | — | Aug 28, 2029 | Common Stock | 4,356 | 62,310 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023.